MarketBeat
08 Aug 2026, 22:05 UTC · 14w ago
Envista Q2 Earnings Call Highlights
Impact · against what's priced in
Envista's raised full-year guidance and strong Q2 margin expansion are positive, but these gains are significantly offset by the quantified risk of price erosion in China. The expectation of a 45% price drop in orthodontics (VBP1) and a 10-15% drop in implants (VBP2) creates a substantial near-term headwind.
- NVST+0.20
No priced-in read yet
- In context
The company raised and narrowed its 2026 guidance and reported a 230 bps expansion in adjusted EBITDA margin to 14.7%, though these gains are tempered by anticipated price compression of 45% for orthodontics and 10-15% for implants in China.
Read from the article alone





